9 Meters Biopharma, Inc.
$NMTR
$1.32
Капитализция: $62.3M
Показать больше информации о компании
О компании
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide,
показать больше
an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease NM-136, a humanized monoclonal antibody for targeted obesity disorders and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease NM-136, a humanized monoclonal antibody for targeted obesity disorders and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
Перевод автоматический
показать меньше
Отчетность
03.11.2021, 23:08
EPS за 3 квартал составил ХХ, консенсус YY
04.08.2021, 23:12
Прибыль на акцию за 2 квартал XX, консенсус-прогноз YY
Квартальная отчетность будет доступна после
Регистрации
Прогнозы аналитиков
Аналитик Аарон Кесслер поддерживает с сильной покупкой и снижает целевую цену со xxx до yyy долларов.
25.10.2021, 16:02
Аналитик Berenberg Сунил Райгопал инициирует освещение на GoDaddy с рейтингом «Покупать» и объявляет целевую цену в xxx долларов.
Прогнозы аналитиков будут доступны после
Регистрации
Все новости компании 9 Meters Biopharma
Новости переведены автоматически
Остальные 14 новостей будут доступны после
Регистрации
Попробуйте все возможности сервиса Tradesense
Моментальные уведомления об измемении цен акций
Новости с официальных сайтов компаний
Прогнозы аналитиков и банков
Регистрация в сервисе
Tradesense доступен на мобильных платформах